Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.68 |
| ▸ | TK2 | O00142 | 2/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.50 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080113 | 1.00 | PYGM (0.68) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4952189 | 0.91 | PYGM (0.56) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL3072346 | 0.90 | PYGM (0.55) | PYGMTK2P2RY2DNPH1 | |
| SCHEMBL3071097 | 0.90 | PYGM (0.55) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL8775826 | 0.88 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL8988015 | 0.88 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL9465813 | 0.88 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL9465927 | 0.88 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL16974933 | 0.86 | PYGM (0.69) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL16974934 | 0.86 | PYGM (0.69) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078080-B1 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | COLEY PHARM GMBH (DE) | 2015-06-17 | — | — | EP | claimed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | claimed |
| CN-113813386-A | Combination tumor immunotherapy | 查克美特制药公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-107428813-B | Combination tumor immunotherapy | 查克美特制药公司 | 2021-08-03 | — | — | CN | disclosed |
| EP-3835312-A1 | COMBINATION TUMOR IMMUNOTHERAPY | Checkmate Pharmaceuticals, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210030783-A1 | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY | CHECKMATE PHARMACEUTICALS, INC. | 2021-02-04 | — | — | US | disclosed |
| EP-3240801-B1 | COMBINATION TUMOR IMMUNOTHERAPY | CHECKMATE PHARMACEUTICALS INC (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3752194-A2 | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY | Checkmate Pharmaceuticals, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200281953-A1 | COMBINATION TUMOR IMMUNOTHERAPY | CHECKMATE PHARMACEUTICALS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-10682365-B2 | Combination tumor immunotherapy | CHECKMATE PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| WO-2019160866-A2 | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY | CHECKMATE PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
| US-20100166780-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | PFIZER INC | 2010-07-01 | — | — | US | disclosed |
| CN-101517082-A | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity | COLEY PHARM GMBH (DE) | 2009-08-26 | — | — | CN | disclosed |
| EP-2054406-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotect GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017515-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| EP-1745061-A1 | NOVEL AMPHIPHILIC COMPOUNDS, PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME | Universite D'Avignon et Des Pays Du Vaucluse (FR) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005116043-A1 | NOVEL AMPHIPHILIC COMPOUNDS, PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME | UNIVERSITE D'AVIGNON ET DES PAYS DE VAUCLUSE (FR) | 2005-12-08 | — | — | WO | disclosed |
| US-5064946-A | 3-azido-2,3-dideoxy-B-D-erythro-pentofuranosyl derivatives of 4(1H)-pyrimidinones; antiretroviral, anti-AIDS | BURROUGHS WELLCOME CO. (US) | 1991-11-12 | — | — | US | disclosed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166780-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | TLR9, TYMP, STING1 | PYGM 3169/4885TK2 58/4885SLC28A1 189/4885 |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | PYGM 1888/4885TK2 34/4885SLC28A1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.